Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · IEX Real-Time Price · USD
1.410
+0.050 (3.68%)
At close: May 31, 2024, 4:00 PM
1.440
+0.030 (2.13%)
After-hours: May 31, 2024, 4:56 PM EDT
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.
The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Neil L. Lerner CPA |
Contact Details
Address: 80 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617-500-8099 |
| Website | compasstherapeutics.com |
Stock Details
| Ticker Symbol | CMPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001738021 |
| CUSIP Number | 20454B104 |
| ISIN Number | US20454B1044 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vered Bisker-Leib M.D., MBA, Ph.D. | Chief Executive Officer |
| Dr. Thomas J. Schuetz M.D., Ph.D. | Co-Founder, President of Research and Development and Vice Chair |
| Neil L. Lerner CPA | Vice President of Finance |
| Jonathan Anderman J.D. | Vice President, Head of Legal and Corporate Secretary |
| Anna Gifford | Communications Manager |
| Dr. Minori Rosales M.D., Ph.D. | Senior Vice President and Head of Clinical Development |
| Karin Herrera B.A. | Vice President and Head of Clinical Operations |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing and Controls |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 28, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | 8-K | Current Report |
| Mar 22, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 21, 2024 | 10-K | Annual Report |